期刊
JOURNAL OF LAW MEDICINE & ETHICS
卷 47, 期 3, 页码 393-395出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/1073110519876170
关键词
-
资金
- Yale University from Johnson and Johnson
- Medtronic, Inc.
- Food and Drug Administration (FDA) [U01FD004585]
- Food and Drug Administration [U01FD005938]
- Blue Cross Blue Shield Association
- Centers of Medicare and Medicaid Services (CMS) [HHSM-500-2013-13018I]
- Agency for Healthcare Research and Quality [R01HS022882]
- National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) [R01HS025164]
- Laura and John Arnold Foundation
- FDA Yale-Mayo Clinic CERSI [U01FD005938]
Surrogate endpoints are a common application of biomarkers to estimate clinical benefit in clinical trials, despite questions about reliability. This article discusses ongoing opportunities for their validation, in the context of a regulatory environment in which they are increasingly championed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
